



Food and Drug Administration  
Rockville MD 20857

APR - 6 2004

Re: Acrysof  
Docket No. 03E-0402

The Honorable Jon Dudas  
Acting Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Acting Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 5,470,932 filed by Alcon under 35 U.S.C. § 156. The medical device claimed by the patent is Acrysof, which was assigned PMA No. P930014/S009.


A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in *Glaxo Operations UK Ltd. v. Quigg*, 706 F. Supp. 1224 (E.D. Va. 1989), *aff'd*, 894 F. 2d 392 (Fed. Cir. 1990).

The PMA was approved on June 24, 2003, which makes the submission of the patent term extension application on July 10, 2003, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

  
Jane A. Axelrad

Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Patrick M. Ryan  
Alcon  
Patent Dept. Q-148  
6201 South Freeway  
Fort Worth, TX 76134

03E-0402

LET 2